The evolution of chloroquine
17 April, 2014A different way of administering chloroquine could see its renewed use to treat malaria.
Innate to start recruiting for SPMS trial in June
16 April, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) expects to start recruiting up to 90 secondary progressive multiple sclerosis patients for a phase IIb trial of MIS416 in June.
Burnet research and development agreement with China
14 April, 2014The Burnet Institute has signed a $5 million agreement with China to support the development of low-cost diagnostic tests.
BioProspect to acquire mental illness test
14 April, 2014 by Dylan Bushell-EmblingBioProspect (ASX:BPO) will acquire a stake in Invatec and a global licence to a potential heart rate-based diagnostics test for a wide range of mental health disorders.
Starpharma secures expanded deal with AstraZeneca
11 April, 2014 by Dylan Bushell-EmblingAstraZeneca has arranged to evaluate using Starpharma's DEP dendrimer drug delivery technology for a second cancer drug.
Minomic plans US trials for prostate cancer test
09 April, 2014 by Dylan Bushell-EmblingMinomic International has tapped CUSP Group to help conduct two US trials of MiSat, a prostate cancer screening tool which has shown signs of being more accurate than the standard PSA test.
Viralytics' Cavatak shows immunotherapy potential
08 April, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) announced that its Cavatak cancer treatment showed signs of oncolytic activity during a phase II trial, and of synergy with a new class of cancer therapy during lab tests.
Regeneus picks US manufacturing partner for Kvax
07 April, 2014 by Dylan Bushell-EmblingRegeneus (ASX:RGS) has selected Hennessy Research to manufacture its canine cancer immunotherapy Kvax for the marketing trials and product launch in the US.
Patrys produces IgM antibodies using plants
03 April, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has published data on a study involving using a plant-based production system to produce IgM antibodies such as the company's anticancer candidate PAT-SM6.
Antisense MS candidate well tolerated in monkeys
02 April, 2014 by Dylan Bushell-EmblingAntisense Therapeutics' (ASX:ANP) in-licensed MS drug candidate ATL1102 was found to be well tolerated at two dose levels during a long-term animal trial.
Prana shares sink after Alzheimer's trial disappoints
02 April, 2014 by Dylan Bushell-EmblingShares in Prana Biotechnology (ASX:PBT) fell 73% after the company revealed that a phase II trial of PBT2 in Alzheimer's disease did not meet its primary and some secondary endpoints.
Indigenous health expert
02 April, 2014 by Susan WilliamsonNutrition scientist and public health researcher Professor Kerin O'Dea discusses a career dedicated to researching diet and chronic disease in Indigenous Australians.
Patrys posts strong results from myeloma trial
27 March, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has said anticancer candidate PAT-SM6 was found to be safe and potentially effective during a phase I/IIa trial in multiple myeloma.
Novogen JV's ovarian cancer drug effective in vivo
26 March, 2014 by Dylan Bushell-EmblingCanTx, a JV between Novogen (ASX:NRT) and Yale University, said its lead drug candidate Trx-1 induced an anti-tumoural effect in a mouse model of ovarian cancer.
Prima adds three more experts to advisory board
26 March, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has chosen three gynaecological oncology experts to join its clinical advisory board as it prepares for a new trial of CVac in epithelial ovarian cancer.
